Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Amgen drug shows high...

    Amgen drug shows high response rate in small lung, colon cancer trial

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-06-14T09:15:16+05:30  |  Updated On 14 Jun 2019 9:15 AM IST
    Amgen drug shows high response rate in small lung, colon cancer trial

    Wall Street has taken a keen interest in the Amgen drug that could become the first approved medicine targeting a mutated form of a gene known as KRAS - one of the most common mutations found in non-small cell lung cancer (NSCLC).


    U.S: An experimental Amgen Inc drug that targets a specific genetic mutation significantly reduced tumour size in half of the evaluated patients with advanced lung cancer in a small, early-stage trial, researchers said on Monday.


    Out of 10 heavily pre-treated lung cancer patients given the oral drug AMG510 daily, five had tumours shrink in size by at least 50%, including one with no evidence of the malignancy.


    The disease was stabilized in another four patients, while cancer progressed in one. Half of the evaluated patients had received the 960-milligram highest dose of AMG510 being tested in the dose-ranging study.


    No serious side effects were reported in data presented in Chicago at the American Society of Clinical Oncology meeting.


    Read Also: Amgen to buy Nuevolution for $167 million


    Wall Street has taken a keen interest in the Amgen drug that could become the first approved medicine targeting a mutated form of a gene known as KRAS - one of the most common mutations found in non-small cell lung cancer (NSCLC).


    NSCLC accounts for up to 85 per cent of lung cancers, by far the leading cause of cancer death among men and women, according to the American Cancer Society.


    Dr Marwan Fakih, co-director of the gastrointestinal cancer program at City of Hope in Duarte, California, who led the study, noted the mild side effect profile compared with treatments like chemotherapy.


    "Patients say they don't know they are even taking anything," he said in a phone interview.


    The targeted mutation, KRASG12C, occurs in around 13% of NSCLC cases, as well as 3-5% of colorectal cancers and up to 2%of other solid tumour cancers, including pancreatic.


    The trial also enrolled patients with colorectal cancer and cancer of the appendix.


    Of 18 colorectal cancer patients evaluated by researchers, 13 achieved stable disease. Most were treated with the two lowest tested doses - 180mg and 360mg.


    The 960mg dose is most likely to be used in future trials, Amgen said.


    AMG510 is part of a growing trend of precision medicines that target gene mutations driving cancer regardless of which organ the disease originated.


    Read Also: Amgen, Syapse enters precision medicine collaboration in Oncology


    "In principle, this drug has the potential to be effective in any patient with the KRAS mutation," Elliott Levy, Amgen's head of global development, said in an interview.


    Other companies, such as Mirati Therapeutics Inc, are also developing drugs that target KRAS mutations, but Amgen's could be first to market.


    "We have a plan to advance the drug rapidly through what would potentially be registrational studies," Levy said.


    The U.S. Food and Drug Administration has granted orphan status to AMG510 for KRASG12C-positive NSCLC and colorectal cancers. The designation brings a longer exclusivity period.


    Amgen has also begun testing AMG510 in combination with Merck & Co's cancer immunotherapy Keytruda, which currently dominates the advanced lung cancer market.

    American Cancer SocietyAmerican Society of Clinical OncologyAMG510AmgenAmgen drugcancercancer immunotherapy Keytrudachemotherapycolon cancerDr Marwan FakihElliott LevyKRAS mutationKRASG12CmalignancyMerckMerck & Conon-small cell lung cancerNSCLCoral drug AMG510small lung cancerUS Food and Drug AdministrationUSFDA
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok